SC
AVDL

Shay Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Shay Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,381
Closed -$214K – 322
2024
Q4 		$214K Sell
20,381
-5,619
-22% -$68.2K 0.03% 251
2024
Q3 		$341K Sell
26,000
-4,000
-13% -$60.9K 0.05% 206
2024
Q2 		$422K Buy
+30,000
New +$489K 0.06% 153
2024
Q1 		– Sell
-14,000
Closed -$198K – 382
2023
Q4 		$198K Buy
+14,000
New +$164K 0.04% 202
2023
Q3 		– Sell
-66,000
Closed -$1.09M – 366
2023
Q2 		$1.09M Buy
+66,000
New +$858K 0.15% 98

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital's AVDL Position: Q1 2025 in Review

Shay Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 20,381 shares — an estimated $214K sold.

Shay Capital first reported a position in AVDL in Q2 2023 and held it in 5 quarters. The position peaked at $1.09M in Q2 2023. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Shay Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Shay Capital sold 20,381 Avadel Pharmaceuticals shares in Q1 2025, an estimated $214K.
  • Shay Capital first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Shay Capital's Avadel Pharmaceuticals position peaked at $1.09M in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.